Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

Sutro Biopharma has demonstrated significant progress in its pipeline, highlighted by the increased valuation of STRO-004 from $25 million to $50 million based on compelling preclinical data, positioning the company favorably ahead of its IND filing. The positive clinical data, particularly for Tivdak, which has shown substantial improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR), underscores the efficacy of its biotherapeutic offerings. With the pending full approval of Tivdak for metastatic cervical cancer in 2024, Sutro Biopharma's growth potential in the biopharmaceutical market appears robust.

Bears say

Sutro Biopharma faces significant challenges related to the efficacy of its therapeutic products, as the preferential binding of its antibodies to specific conformations may hinder their effectiveness in achieving uniform tumor targeting. This limitation is expected to adversely impact the performance of antibody-drug conjugates (ADCs), leading to potential issues with internalization, payload delivery, and overall treatment efficacy. Additionally, the negative ramifications seen with comparable therapies, such as off-tissue toxicity observed with Tivdak, raise concerns about the safety profile of Sutro's product pipeline.

STRO has been analyzed by 6 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Hold based on their latest research and market trends.

According to 6 analysts, STRO has a Hold consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.